Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Input: Consider Input: The case, published in The Lancet medical journal, involved connecting veins from the donor uterus with the recipient’s veins, as well as linking arteries, ligaments and vaginal canals. It comes after 10 previously known cases of uterus transplants from deceased donors - in the United States, the Czech Republic and Turkey - failed to produce a live birth. The girl born in the Brazilian case was delivered via caesarean section at 35 weeks and three days, and weighed 2,550 grams (nearly 6 lbs), the case study said. Dani Ejzenberg, a doctor at Brazil’s Sao Paulo University hospital who led the research, said the transplant - carried out in September 2016 when the recipient was 32 - shows the technique is feasible and could offer women with uterine infertility access to a larger pool of potential donors. The current norm for receiving a womb transplant is that the organ would come from a live family member willing to donate it. “The numbers of people willing and committed to donate organs upon their own deaths are far larger than those of live donors, offering a much wider potential donor population,” Ejzenberg said in a statement about the results. She added, however, that the outcomes and effects of womb donations from live and deceased donors have yet to be compared, and said the technique could still be refined and optimized. The first baby born after a live donor womb transplant was in Sweden in 2013. Scientists have so far reported a total of 39 procedures of this kind, resulting in 11 live births. Experts estimate that infertility affects around 10 to 15 percent of couples of reproductive age worldwide. Of this group, around one in 500 women have uterine problems. Before uterus transplants became possible, the only options to have a child were adoption or surrogacy. In the Brazilian case, the recipient had been born without a uterus due to a condition called Mayer-Rokitansky-Küster-Hauser syndrome. The donor was 45 and died of a stroke. Five months after the transplant, Ejzenberg’s team wrote, the uterus showed no signs of rejection, ultrasound scans were normal, and the recipient was having regular menstruation. The woman’s previously fertilized and frozen eggs were implanted after seven months and 10 days later she was confirmed pregnant. At seven months and 20 days - when the case study report was submitted to The Lancet - the baby girl was continuing to breastfeed and weighed 7.2 kg (16 lb).

Output: World's first baby born via womb transplant from dead donor.


Input: Consider Input: Chaiya, under pressure from health activists and doctors who campaigned to have him sacked, said declaring compulsory licenses on the drugs would save Thailand more than 3 billion baht ($100 million) over the next five years. “The findings have convinced me to go ahead with the CLs since the ministry’s policy is to give patients good access to quality drugs at cheap prices,” Chaiya said of the review by a panel of Health Ministry officials. The decision is a blow to major pharmaceutical companies which had lobbied hard to reverse the CL policy launched by the previous government appointed after a bloodless 2006 coup. The three drugs are Letrozole, a breast cancer medicine made by Novartis AG, the breast and lung cancer drug Docetaxel by Sanofi-Aventis, and Roche’s Erlotinib, used for treating lung, pancreatic and ovarian cancer. A license issued on a leukemia drug, Glivec, was cancelled last month after its maker, Novartis, agreed to supply it free to hundreds of Thai patients. Shortly after a democratically-elected government took power in February, Chaiya ordered the review of a policy he said was a “politically correct decision, but not legally correct”. At the time he said the government could afford the full cost of the drugs, if it meant avoiding trade retaliation by the United States, home to some of the world’s biggest drug firms. U.S. officials denied there were any plans to impose sanctions on Bangkok, although Thailand was placed on a watch list, meaning Washington believed its respect for patents had weakened. When Chaiya, a businessman with no medical training, fired the Health Ministry’s top official negotiating cheaper prices from foreign drug firms, outraged health activists and doctors launched a campaign to remove him. Chaiya said on Monday the ministry would buy cheaper versions of the cancer drugs from generic producers, such as Indian firms which already supply copy-cat HIV-AIDS medicines to Thailand. Under World Trade Organisation rules, countries can issue a compulsory license to make or buy generic versions of patented drugs deemed critical to public health as long as the medicines are meant for domestic use. Former Health Minister Mongkol na Songkhla overrode Merck’s AIDS drug Efavirenz in late 2006, arguing that Thailand could not afford patented drugs for a national health plan that covers about 80 percent of the country’s 63 million people. A few months later he did the same on a Sanofi-Aventis heart medicine and an AIDS drug made by Abbott Laboratories, which refused to register several new medicines in Thailand. Mongkol, who targeted the four cancer drugs weeks before he left office, has defended the CL policy against major drug firms which accused him of stealing their intellectual property rights. ($1= 30 Baht)

Output: Thailand will override cancer drug patents.


Input: Consider Input: In a joint statement after a five-day conference in Britain, the international experts said snake bites kill more people than all other so-called Neglected Tropical Diseases combined, yet get little attention or funding from the World Health Organisation (WHO) or from governments. Citing new evidence from a study in India and Bangladesh, the experts said around 46,000 people died annually of snake bites in India, plus another 6,000 in Bangladesh. The WHO estimates the annual death toll in India from snake bites is 10,000. “Snake bite ... is almost completely ignored and grossly underestimated,” said Alan Harvey, head of the International Society of Toxinology, who led the meeting. “WHO and governments need to ... rank snake bite where it belongs — as a very real public health and medical concern which needs funding, training and focus.”  Bites from snakes such as cobras, mambas and vipers mainly affect people living in rural areas of sub-Saharan Africa, South Asia and Southeast Asia with scant health facilities nearby. Antivenom treatment can cost between $250 and $500, the experts said, meaning many victims either seek no treatment at all or go to local witch doctors or herbalists. Despite high death rates, the WHO in 2013 downgraded snake bite to a “neglected condition” with no formal program on how to address it as a health threat, the experts said. The specialists also warned that antivenom stocks are running “dangerously low” in many risk areas and said there is a “real crisis in the quantity and quality of antivenoms in rural areas, where they are needed most”. Even where antivenom stocks are good and of high quality, there is often a shortage of medical staff trained in how to administer them safely or effectively.


Output: Venom experts say global snake bite death tolls 'grossly underestimated'.